HORN JURGEN 4
4 · Nexvet Biopharma plc · Filed Aug 2, 2017
Insider Transaction Report
Form 4
HORN JURGEN
Chief Product Development Ofcr
Transactions
- Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−47,250$311,614→ 0 totalExercise: $0.13Exp: 2021-07-01→ Ordinary Shares (47,250 underlying) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−15,750$105,840→ 0 total - Disposition to Issuer
Option to purchase Ordinary Shares
2017-07-31$1.62/sh−60,000$97,200→ 0 totalExercise: $5.10Exp: 2022-08-26→ Ordinary Shares (60,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer (the "Acquisition")
- [F2]This option to purchase Ordinary Shares, which would have vested as to 12,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18, 12/31/18, 3/31/19 and 6/30/19, was cancelled in the Acquisition in exchange for a cash payment equal to $97,200. This amount represents the difference between such exercise price per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on exercise of the option.
- [F3]This restricted share unit, which would have vested and become convertible as to 15,750 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $311,613.75. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.